β2-Agonist Therapy in Lung Disease

M Cazzola, CP Page, P Rogliani… - American journal of …, 2013 - atsjournals.org
β2-Agonists are effective bronchodilators due primarily to their ability to relax airway smooth
muscle (ASM). They exert their effects via their binding to the active site of β2-adrenoceptors …

2-Phenethylamines in medicinal chemistry: A review

CT Nieto, A Manchado, L Belda, D Diez, NM Garrido - Molecules, 2023 - mdpi.com
A concise review covering updated presence and role of 2-phenethylamines in medicinal
chemistry is presented. Open-chain, flexible alicyclic amine derivatives of this motif are …

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group …

MT Dransfield, J Bourbeau, PW Jones… - The Lancet …, 2013 - thelancet.com
Background Whether the combination of a once-daily inhaled corticosteroid with a once-
daily longacting β 2 agonist is more protective than a once-daily longacting β 2 agonist …

β2‐adrenoceptor agonists and antagonists and risk of Parkinson's disease

N Gronich, DR Abernethy, E Auriel, I Lavi… - Movement …, 2018 - Wiley Online Library
Background: β2‐adrenoreceptors have recently been identified as regulators of the α‐
synuclein gene, which is implicated in the pathogenesis of Parkinson's disease. Objective …

G protein–coupled receptors in asthma therapy: pharmacology and drug action

SG Wendell, H Fan, C Zhang - Pharmacological reviews, 2020 - Elsevier
Asthma is a heterogeneous inflammatory disease of the airways that is associated with
airway hyperresponsiveness and airflow limitation. Although asthma was once simply …

Pharmacologic Activities of Plant‐Derived Natural Products on Respiratory Diseases and Inflammations

D Timalsina, KP Pokhrel… - BioMed Research …, 2021 - Wiley Online Library
Respiratory inflammation is caused by an air‐mediated disease induced by polluted air,
smoke, bacteria, and viruses. The COVID‐19 pandemic is also a kind of respiratory disease …

The beta2‐adrenergic receptor – a re‐emerging target to combat obesity and induce leanness?

M Hostrup, J Onslev - The Journal of Physiology, 2022 - Wiley Online Library
Abstract Treatment of obesity with repurposed or novel drugs is an expanding research field.
One approach is to target beta2‐adrenergic receptors because they regulate the metabolism …

[HTML][HTML] Current approaches to the discovery of novel inhaled medicines

P Strong, K Ito, J Murray, G Rapeport - Drug discovery today, 2018 - Elsevier
Highlights•Inhaled medicines are cornerstones in the treatment of asthma/COPD
today.•Significant unmet medical need remains in the treatment of respiratory diseases.•The …

Back to the future: re-establishing guinea pig in vivo asthma models

M Adner, BJ Canning, H Meurs, W Ford… - Clinical …, 2020 - portlandpress.com
Research using animal models of asthma is currently dominated by mouse models. This has
been driven by the comprehensive knowledge on inflammatory and immune reactions in …

Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy

L Calzetta, MG Matera, M Cazzola - Current opinion in pharmacology, 2018 - Elsevier
Highlights•Dual bronchodilator therapy has clinical benefits in COPD.•Combining a LABA
with a LAMA synergistically relaxes medium and small airways.•In some approved …